{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T05:29:41Z","timestamp":1670477381958},"reference-count":22,"publisher":"Galenos Yayinevi","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2022.2022.0045","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T06:03:40Z","timestamp":1665036220000},"page":"237-244","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study)"],"prefix":"10.4274","volume":"39","author":[{"given":"Sevgi","family":"I\u015f\u0131k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl\u00e7in","family":"G\u00fcnden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hava","family":"\u00dcsk\u00fcdar Teke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Meltem","family":"Akay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur","family":"O\u011fuz Davuto\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahap","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Karag\u00fclle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fclya","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O\u011fuz","family":"\u00c7ilingir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevilhan","family":"Artan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beyhan","family":"Durak Aras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3324\/haematol.11064","article-title":"Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure","volume":"92","author":"Fabarius","year":"2007","unstructured":"1. Fabarius A, Haferlach C, M\u00fcller MC, Erben P, Lahaye T, Giehl M, Frank O, Seifarth W, Hehlmann R, Hochhaus A. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007;92:834-837.","journal-title":"Haematologica"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fonc.2019.00088","article-title":"Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia","volume":"9","author":"Krishna Chandran","year":"2019","unstructured":"2. Krishna Chandran R, Geetha N, Sakthivel KM, Suresh Kumar R, Jagathnath Krishna KMN, Sreedharan H. Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia. Front Oncol 2019;9:88.","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/sj.leu.2403607","article-title":"Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha","volume":"19","author":"Bacher","year":"2005","unstructured":"3. Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlach T, Schoch C. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005;19:460-463.","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"Schoch","year":"2003","unstructured":"4. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochhaus A. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003;17:461-463.","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","unstructured":"5. Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, G\u00f6hring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, H\u00e4nel M, K\u00f6hne CH, Lindemann HW, Berdel WE, Staib P, M\u00fcller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Br\u00fcmmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Sau\u00dfele S, Hehlmann R; SAKK and the German CML Study Group. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol 2015;94:2015-2024.","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/s41375-020-01039-7","article-title":"Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","unstructured":"6. Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spie\u00df B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Br\u00fcmmendorf TH, Hasford J, Hochhaus A, Sau\u00dfele S, Baccarani M; SAKK and the German CML Study Group. Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020;34:2823.","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","unstructured":"7. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966-984.","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","unstructured":"8. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 2018;93:84-90.","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression","volume":"5","author":"Clark","year":"2021","unstructured":"9. Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv 2021;5:1102-1109.","journal-title":"Blood Adv"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","unstructured":"10. Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012;120:761-767.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","unstructured":"11. Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen JL, McDonnell TJ, Wang W, Kantarjian HM, Hu S. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv 2017;1:2541-2552.","journal-title":"Blood Adv"},{"key":"ref11","unstructured":"12. Oudat R, Khan Z, Glassman AB. Detection of trisomy 8 in philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement. Ann Clin Lab Sci 2001;31:68-74."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/leu.2015.96","article-title":"Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"29","author":"Wang","year":"2015","unstructured":"13. Wang W, Cortes JE, Lin P, Khoury JD, Ai D, Tang Z, Tang G, Jorgensen JL, Medeiros LJ, Hu S. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia 2015;29:2263-2266.","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","unstructured":"14. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016;127:2742-2750.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Noveski P, Madjunkova S, Sukarova Stefanovska E, Matevska Geshkovska N, Kuzmanovska M, Dimovski A, Plaseska-Karanfilska D. Loss of Y chromosome in peripheral blood of colorectal and prostate cancer patients. PLoS One 2016;11:e0146264.","DOI":"10.1371\/journal.pone.0146264"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Wang W, Chen Z, Hu Z, Yin CC, Li S, Bai S, Bueso-Ramos CE, Medeiros LJ, Hu S. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer J. 2016;6:e490.","DOI":"10.1038\/bcj.2016.96"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","unstructured":"17. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 2017;130:2084-2091.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2009.019109","article-title":"Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy","volume":"95","author":"Lippert","year":"2010","unstructured":"18. Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S, Gachard N, Tigaud I, Dastugue N, Huguet F, Fort MP, Legros L, Eclache V, Mahon FX. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica 2010;95:1604-1607.","journal-title":"Haematologica"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/sj.leu.2403779","article-title":"Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability","volume":"19","author":"Giehl","year":"2005","unstructured":"19. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, Seifarth W. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 2005;19:1192-1197.","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.leukres.2008.01.011","article-title":"Trisomy 6 in a CML patient receiving imatinib mesylate therapy","volume":"32","author":"Z\u00e1mecn\u00edkova","year":"2008","unstructured":"20. Z\u00e1mecn\u00edkova A, Al Bahar S, Ramesh P. Trisomy 6 in a CML patient receiving imatinib mesylate therapy. Leuk Res 2008;32:1454-1457.","journal-title":"Leuk Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0165-4608(86)90215-3","article-title":"Trisomy 11 in a patient with Ph-negative chronic myelogenous leukemia","volume":"21","author":"Yamada","year":"1986","unstructured":"21. Yamada T, Sasaki M, Kawamura T. Trisomy 11 in a patient with Ph-negative chronic myelogenous leukemia. Cancer Genet Cytogenet 1986;21:343-345.","journal-title":"Cancer Genet Cytogenet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13039-015-0204-x","article-title":"23), tetrasomy 8 and trisomy 19 in a blast crisis-chronic myeloid leukemia after interrupted Imatinib-treatment","volume":"8","author":"Wafa","year":"2015","unstructured":"22. Wafa A, Almedani S, Liehr T, Al-Achkar W. Masked inv dup(22)(q11.23), tetrasomy 8 and trisomy 19 in a blast crisis-chronic myeloid leukemia after interrupted Imatinib-treatment. Mol Cytogenet 2015;8:98.","journal-title":"Mol Cytogenet"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:43:20Z","timestamp":1670413400000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-22623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2022.2022.0045","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}